Date
Title
Date
09/19/22
Title
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
Date
09/07/22
Title
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
Date
09/06/22
Title
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Date
08/04/22
Title
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Date
08/02/22
Title
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
Date
07/12/22
Title
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
Date
07/12/22
Title
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
Date
06/08/22
Title
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
Date
06/01/22
Title
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
Date
05/26/22
Title
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting